JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prunier, C.
Right arrow Articles by Baulieu, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prunier, C.
Right arrow Articles by Baulieu, J.-L.

Quantification of Dopamine Transporter by 123I-PE2I SPECT and the Noninvasive Logan Graphical Method in Parkinson’s Disease

Caroline Prunier, MD1, Pierre Payoux, MD2, Denis Guilloteau, PhD1, Sylvie Chalon, PhD1, Bruno Giraudeau, PhD3, Cynthia Majorel, PhD2, Mathieu Tafani, PhD2, Erwan Bezard, PhD4, Jean-Paul Esquerré, PhD2 and Jean-Louis Baulieu, PhD1

1 Nuclear Medicine Department, Institut National de la Santé et de la Recherche Médicale Unit 316, Bretonneau Hospital, Tours, France
2 Nuclear Medicine Department Équipe d’Accueil 3033, Purpan Hospital, Toulouse, France
3 Clinical Research Center, François Rabelais University, Tours, France
4 Basal Gang, Laboratoire de Neurophysiologie, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5543, Victor Segalen University, Bordeaux, France



View larger version (50K):

[in a new window]
 
FIGURE 1. 123I-PE2I SPECT (acquisition between 35 and 50 min after injection) of healthy volunteer and 4 PD patients according to 4 stages of Hoehn and Yahr clinical score. All PD patients are characterized by progressive reductions in dopamine nigrostriatal terminal density, first in putamen and then in caudate nucleus.

 


View larger version (16K):

[in a new window]
 
FIGURE 2. Kinetics of 123I-PE2I in striatum (caudate nucleus and putamen) and occipital lobe in healthy volunteer (A) and parkinsonian patient (B) according to 4 sequential SPECT acquisitions. (C) Quantification of distribution volume of 123I-PE2I in striatum according to slope of Logan plot in healthy volunteers and parkinsonian patients.

 


View larger version (17K):

[in a new window]
 
FIGURE 3. Distribution volume of 123I-PE2I in caudate nucleus, putamen, right striatum (rS), left striatum (lS), and striatum in 8 healthy volunteers ({diamondsuit}) and 8 parkinsonian patients ({circ}).

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.